文献速递神经肿瘤

胶质瘤PET成像:现状与未来方向

PET imaging of gliomas: Status quo and quo vadis?
PubMed 文献 · Neuro Oncol · 2024-01-01

本文综述氨基酸类示踪剂PET在胶质瘤临床管理中的作用,指出其已成为解剖MRI的有价值补充,国际协作已推动胶质瘤PET临床与技术指南制定,欧洲部分法定医保机构对氨基酸PET报销意愿增强;文章还讨论人工智能与影像组学、长轴视野PET/CT、治疗相关靶点示踪剂及诊疗一体化等新方向,并指出这些创新有待近期进一步验证。

要点

  • 氨基酸PET是胶质瘤解剖MRI的有价值补充,已推动国际临床与技术指南制定。
  • 欧洲部分法定医保机构对氨基酸PET报销意愿增强,凸显其临床重要性。
  • 人工智能与影像组学、长轴视野PET/CT及治疗靶点示踪剂等创新有待近期进一步验证。

核心结论

  • 氨基酸示踪剂PET已成为胶质瘤临床管理中解剖MRI的有价值辅助手段,国际协作已促成相关临床与技术指南。
  • 欧洲部分法定医保机构对氨基酸PET报销意愿增强,体现其在临床实践中的重要性上升。
  • 人工智能与影像组学、长轴视野PET/CT、治疗相关靶点示踪剂及诊疗一体化等进展拓展了PET在神经肿瘤学中的作用,但这些创新有待近期进一步验证。

研究设计与样本

  • 本文为综述,围绕胶质瘤PET成像的临床应用现状与未来方向进行论述,并提及国际协作制定的胶质瘤PET临床与技术指南。

主要发现

  • 氨基酸示踪剂PET已成为胶质瘤患者临床管理中解剖MRI的有价值辅助手段。
  • 欧洲部分法定医保机构对氨基酸PET报销意愿增强。
  • 将人工智能与影像组学整合入胶质瘤PET成像可能显著改善肿瘤检测、分割与疗效评估。
  • 长轴视野PET/CT等下一代PET扫描仪改善了图像质量与全身覆盖范围,扩展了神经肿瘤学中PET成像的适应证(如全脊柱PET成像)。
  • 胶质瘤临床试验的鼓舞性结果推动了针对治疗相关靶点(如突变型异柠檬酸脱氢酶)的PET示踪剂开发,用于改善新型抗癌药物的疗效评估。

临床怎么用

  • 作者指出,这些进展凸显PET成像在神经肿瘤学中不断演变的作用,可提供肿瘤生物学与治疗反应的洞见,从而指导个体化患者诊疗。
  • 作者指出,上述创新有待近期进一步验证。

局限性

  • 原文指出这些创新有待近期进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PET imaging, particularly using amino acid tracers, has become a valuable adjunct to anatomical MRI in the clinical management of patients with glioma. Collaborative international efforts have led to the development of clinical and technical guidelines for PET imaging in gliomas. The increasing readiness of statutory health insurance agencies, especially in European countries, to reimburse amino acid PET underscores its growing importance in clinical practice. Integrating artificial intelligence and radiomics in PET imaging of patients with glioma may significantly improve tumor detection, segmentation, and response assessment. Efforts are ongoing to facilitate the clinical translation of these techniques. Considerable progress in computer technology developments (eg quantum computers) may be helpful to accelerate these efforts. Next-generation PET scanners, such as long-axial field-of-view PET/CT scanners, have improved image quality and body coverage and therefore expanded the spectrum of indications for PET imaging in Neuro-Oncology (eg PET imaging of the whole spine). Encouraging results of clinical trials in patients with glioma have prompted the development of PET tracers directing therapeutically relevant targets (eg the mutant isocitrate dehydrogenase) for novel anticancer agents in gliomas to improve response assessment. In addition, the success of theranostics for the treatment of extracranial neoplasms such as neuroendocrine tumors and prostate cancer has currently prompted efforts to translate this approach to patients with glioma. These advancements highlight the evolving role of PET imaging in Neuro-Oncology, offering insights into tumor biology and treatment response, thereby informing personalized patient care. Nevertheless, these innovations warrant further validation in the near future.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Galldiks N, Lohmann P, Friedrich M, et al. PET imaging of gliomas: Status quo and quo vadis? Neuro Oncol. 2024. PMID: 38970818. doi:10.1093/neuonc/noae078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。